Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / GPR65



This biomarker is also known as:
  • Q8IYL9,
  • G-protein coupled receptor 65,
  • G protein-coupled receptor 65,
  • TDAG8,
  • T-cell death-associated gene 8 protein,
  • psychosine receptor,
  • hTDAG8,

View in BioMuta


GPR65, a member of the G-protein coupled receptor 1 family, is a receptor for the glycosphingolipid psychosine (PSY) and several related glycosphingolipids. GPR65 may have a role in activation-induced cell death or differentiation of T-cells. It is expressed in thymus, spleen, lymph nodes, small intestine, lung, placenta and peripheral blood leukocytes.


QA State: Curated
Type: Protein
Short Name:
HGNC Name: GPR65


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


No additional ovarian data available.

Performance Comment

GPR65 was one of 50 tumor vasculature-associated genes with transmembrane or secreted protein products identified through expression profiling of ovarian cancer vascular cells. These 50 tumor vascular markers (TVMs) also had low or no expression in normal tissues. GPR65 was not in the group of 13 selected for further validation.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.